Your search for bevacizumab returned 6 results

Bevacizumab-adcd 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.

Bevacizumab-bvzr 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.

The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.

Researchers looked at the use of 6 biosimilars across 38 oncology practices and found that biosimilar use increased from 2019 to 2021.

Increased recurrence-free survival seen for patients with high-risk HCC following resection or ablation.

High drug prices and ongoing shortages may prompt cancer patients to buy treatments online and fall prey to illegitimate pharmacies.